- Home
- MTR vs BIAF Comparison
MTR vs BIAF Comparison
Compare MTR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- BIAF
- Stock Information
- Founded
- MTR 1979
- BIAF 2014
- Country
- MTR United States
- BIAF United States
- Employees
- MTR N/A
- BIAF N/A
- Industry
- MTR Oil & Gas Production
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MTR Energy
- BIAF Health Care
- Exchange
- MTR Nasdaq
- BIAF Nasdaq
- Market Cap
- MTR 10.9M
- BIAF 12.2M
- IPO Year
- MTR N/A
- BIAF 2022
- Fundamental
- Price
- MTR $5.86
- BIAF $0.30
- Analyst Decision
- MTR
- BIAF Hold
- Analyst Count
- MTR 0
- BIAF 1
- Target Price
- MTR N/A
- BIAF N/A
- AVG Volume (30 Days)
- MTR 7.1K
- BIAF 1.8M
- Earning Date
- MTR 01-01-0001
- BIAF 08-13-2025
- Dividend Yield
- MTR 3.60%
- BIAF N/A
- EPS Growth
- MTR N/A
- BIAF N/A
- EPS
- MTR 0.23
- BIAF N/A
- Revenue
- MTR $668,826.00
- BIAF $8,809,228.00
- Revenue This Year
- MTR N/A
- BIAF N/A
- Revenue Next Year
- MTR N/A
- BIAF $20.00
- P/E Ratio
- MTR $25.79
- BIAF N/A
- Revenue Growth
- MTR N/A
- BIAF 78.40
- 52 Week Low
- MTR $4.70
- BIAF $0.16
- 52 Week High
- MTR $10.42
- BIAF $2.41
- Technical
- Relative Strength Index (RSI)
- MTR 55.20
- BIAF 45.59
- Support Level
- MTR $5.47
- BIAF $0.28
- Resistance Level
- MTR $5.98
- BIAF $0.35
- Average True Range (ATR)
- MTR 0.23
- BIAF 0.03
- MACD
- MTR 0.02
- BIAF -0.01
- Stochastic Oscillator
- MTR 84.21
- BIAF 24.06
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.